Topic
Tyrosine Kinase Inhibitor (TKI)
2 Podcasts on BackTable
Episode # 513 • 31 Jan 2025
Combination Therapy & Clinical Trials for Advanced HCC: What They Really Mean
In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman.
This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific.
More on Tyrosine Kinase Inhibitor (TKI)
Loading recent podcasts…
VI Episode #513
Jan 31, 2025
with Dr. Lingling Du, Dr. Jonathan Mizrahi, Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Tyler Sandow
In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative...
3,800+ listens
Tumor Board Episode #3
Jan 17, 2025
with Dr. Lingling Du, Dr. Jonathan Mizrahi, Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Tyler Sandow
In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative...
3,800+ listens
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.